Wells Fargo & Company MN Has $11.19 Million Stock Position in Bruker Co. (NASDAQ:BRKR)

Wells Fargo & Company MN raised its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 95.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 190,855 shares of the medical research company's stock after acquiring an additional 93,048 shares during the period. Wells Fargo & Company MN owned approximately 0.13% of Bruker worth $11,188,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of BRKR. Eagle Bay Advisors LLC raised its stake in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Bruker by 37.5% during the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after acquiring an additional 248 shares in the last quarter. GAMMA Investing LLC raised its position in Bruker by 47.5% during the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after purchasing an additional 412 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in Bruker by 41.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after purchasing an additional 390 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Bruker by 13.5% in the 4th quarter. Blue Trust Inc. now owns 2,164 shares of the medical research company's stock valued at $127,000 after purchasing an additional 257 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors.

Bruker Trading Down 3.9 %

Shares of NASDAQ:BRKR traded down $1.46 during midday trading on Friday, reaching $36.28. The company's stock had a trading volume of 3,551,073 shares, compared to its average volume of 1,498,213. The firm has a 50 day moving average price of $44.52 and a two-hundred day moving average price of $53.58. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $83.32. The firm has a market capitalization of $5.50 billion, a price-to-earnings ratio of 47.74, a PEG ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60.

Bruker (NASDAQ:BRKR - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. As a group, analysts forecast that Bruker Co. will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were issued a dividend of $0.05 per share. The ex-dividend date was Monday, March 17th. This represents a $0.20 annualized dividend and a dividend yield of 0.55%. Bruker's dividend payout ratio is currently 26.32%.

Analyst Ratings Changes

BRKR has been the topic of a number of recent analyst reports. Wells Fargo & Company decreased their target price on Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research report on Thursday. Citigroup decreased their target price on shares of Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Stifel Nicolaus cut their price objective on Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a report on Friday, February 14th. Guggenheim reiterated a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Barclays reduced their price objective on shares of Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Six investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $65.00.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.